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were identiﬁed and mapped based on the ultrasound image. Dose optimization was done on the reconstructed applicator geom-
etry using dose point and manual optimization algorithms to determine dwell positions and times. To decrease rectal toxicity,
transperineal hyaluronic acid injection into the peri-rectal fat was used to consistently displace the rectal wall away from the
radiation sources in all patients. To decrease genitourinary toxicity, urethal hypothermia was used. The prostate without safety
margins was then deﬁned as the planning target volume (PTV) to be treated with the prescribed dose (PD). All patients were
discharged from the center on the same day of the procedure between 6-8 hours of implantation.
Conclusions. This treatment is feasible with advantages compared to LDR and HDR brachytherapy as monotherapy using the
fractionation schedule of 4 fractions administered 2 times daily during two days and may involve a change in the therapeutic
strategy of this tumor.
http://dx.doi.org/10.1016/j.rpor.2013.03.684
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Introduction. Image guide radiotherapy (IGRT), hialuronic acid inyection and Intensity Modulated Radiation Therapy (IMRT) are
an advantage strategy in moderate hypofractionated radiation therapy in prostate cancer.
Objective. To describe how IGRT, hialuronic (HA) acid inyection and IMRT have been incorporated to improve accurate and safety
for hypofractionated treatment in prostate cancer in our institution.
Methods. We investigated a moderate hypofractionated protocol to treat low and intermediate risk prostate cancer with dose-
escalated since 63Gy in 21 fractions (3Gy/day) until 52Gy in 13 fractions (4Gy/day). The procedure will be performed in lithotomy
position of the patient under sedation within 15–20min. Previously to treatment administration, transperineally and guided by
transrectal ultrasound, HA was placed in the perirectal fat, in order to protect the rectum and optimize the dose. In the same
procedure a ﬁducial internal marker (Visicoil®) was placed within the prostate gland. External infrared spheras were used during
the CT simulation. The treatment was realized with IMRT with “sliding windows”, in the Novalis Linac (Brainlab®), adapted to
stereotactic treatments. Daily veriﬁcation of the treatment was performed with IGRT Exactrac system, using a 6D robotic cough,
infrared camera and orthogonal X-rays. We have not seen side effects and not complications related to the injection or the
compound itself and ﬁducial internal marker (Visicoil®) placed. There is no toxicity in the fat tissue or in rectal function.
Conclusions. Moderate hypofractionated radiotherapy with IGRT (ﬁducial internal markers), HA inyection and IMRT, is a feasible,
safety and accurate treatment for low and intermediate risk prostate cancer.
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Introduction. After external radiotherapy laparoscopic radical prostatectomy can get similar control in prostatic cancer compared
with the standard radical prostatectomy, however it’s rarely permorfed. The use of brachytherapy as a curative treatment option
has increased in recent years. Likewise, the biochemical relapse and failure after radiotherapy is becoming increasingly common
and it’s considered a therapeutic challenge, especially in patients with local recurrence, low comorbidity, life expectancy of at
least 10 years, CT1-T2, Gleason <7 and preoperative PSA <10ng/ml.
Case report. A 65 years old male with a body mass index of 31.93kg/m2, with an initial PSA of 5.93ng/ml in 2007. Prostatic biopsy
determined a well-differentiated prostate adenocarcinoma Gleason 4 (2 + 2) in the left lobe, whereby the patient received external
radiotherapy by administering a total of 77.7 Gy, achieving a nadir PSA of 1.1 ng/ml in October 2007. Since then PSA levels started
rising up gradually reaching 3.6 ng/ml in August 2009. We think that the patient had a local recurrence, cause bone scintigraphy
was negative and MRI determined a nodule of 15 mm in the left lobe supporting neoplasia. A prostatic biopsy reported focus of
adenocarcinoma in the two lobes and changes attributable to radiation therapy. We present a video of radiotherapy laparoscopic
radical prostatectomy with a surgical time of 250min. The hospital stay was 5 days. The pathologic report determined a lobar
acinar adenocarcinoma (residual tumor), a high grade PIN, edges and vesicles respected, ductoacinar epithelial changes and
ﬁbrosis secondary to radiation therapy.
Conclusion. After external radiotherapy laparoscopic radical prostatectomy is a complex technique that can be offered to patients
with less comorbidity and life expectancy greater than 10 years. Based on the published data, good local control rates can be
reached with 30–50% recurrence-free survival and 70–77% speciﬁc-disease survival at 10 years.
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